Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04397003
Title Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine

lung small cell carcinoma


Carboplatin + Durvalumab + Etoposide

Durvalumab + Tremelimumab

Durvalumab + Personalized cancer vaccine + Tremelimumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.